Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -80.82% | -360.53% | -285.99% | -254.34% | -- |
| Total Depreciation and Amortization | 46.27% | 50.27% | 32.31% | -7.95% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,568.47% | 314.84% | 250.31% | 300.17% | -- |
| Change in Net Operating Assets | 240.31% | 1,400.75% | 620.90% | -118.58% | -- |
| Cash from Operations | -42.66% | -336.38% | -269.75% | -228.38% | -- |
| Capital Expenditure | 43.22% | 18.66% | -24.15% | -525.71% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.59% | 3.84% | -6.28% | 27.15% | -- |
| Cash from Investing | 82.23% | 3.98% | -6.36% | 26.35% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -99.13% | 39,791.21% | 68,454.09% | 99,357.80% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 48.69% | 128.99% | 100.00% | -- | -- |
| Cash from Financing | -99.35% | 92.06% | 94.03% | 93.37% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -324.34% | -13.82% | -35.55% | 92.08% | -- |